The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2022 | ImmunoVax: neutralizing responses in cancer patients and variants in regards to COVID19
Michel Obeid, MD, PhD, CHUV – Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, talks on the ImmunoVax comparative effectiveness study. The study assessed the difference in magnitude and durability of the neutralizing antibody (nAbs) response against the nonvariant SARS-VoV-2 and the SARS-Cov-2 variants of convern (VOCs), Alpha, Beta, Gamma, and Delta, according to the type of vaccination, Moderna versus Pfizer. 637 immunocompromised patients were involved in the comparative study, including 204 healthy controls, 400 patients with solid cancer and 100 patients with hematologic cancers. The study demonstrated for the first time considerable differences in waning of the nAb responses in the nonvariant and the VOCs. Additionally, patients vaccinated with Moderna showed a higher humoral response compared to Pfizer in terms of magnitude and duration. This interview took place during the virtual European Lung Cancer Congress 2022.
